LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.Blood Adv入排复审未纳入:The abstract describes a secondary/safety analysis of a subgroup (patients transitioning from ibrutinib to zanubrutinib) within the context of the Phase 3 ASPEN trial, but does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier curves) from the randomized comparison. Therefore, it does not meet the inclusion criteria for a Phase III randomized trial with a primary/key secondary time-to-event efficacy endpoint. | PMID 40924923PMC12767813 | 2025-Dec-23 | 0.85 | The abstract describes a secondary/safety analysis of a subgroup (patients transitioning from ibrutinib to zanubrutinib) within the context of the Phase 3 ASPEN trial, but does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier curves) from the randomized comparison. Therefore, it does not meet the inclusion criteria for a Phase III randomized trial with a primary/key secondary time-to-event efficacy endpoint. | 无 KM 图 |
| Pharmacogenomic, pharmacokinetic, and safety analysis of CYP3A4/CYP3A5 polymorphisms of midostaurin in patients with acute myeloid leukemia.Eur J Clin PharmacolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41432755无 PMCID | 2025-Dec-23 | 0.80 | The study is from a definitive Phase III RCT but is a secondary analysis focused on pharmacogenomics, pharmacokinetics, and safety, not efficacy outcomes like survival or progression. | 无 KM 图 |
| Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.J Clin Oncol | PMID 41037766PMC12711268 | 2025-Dec-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Cost and cost-effectiveness of attractive targeted sugar baits (ATSB) in the context of a phase III cluster randomized control trial in Western Province, Zambia.Malar J已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other。 | PMID 41420162PMC12831337 | 2025-Dec-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β-catenin vulnerability in T-ALL.BloodPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40857670无 PMCID | 2025-Dec-18 | 0.45 | The study analyzes genetic alterations (LEF1) in T-ALL cohorts from completed trials and explores a biological mechanism. While it mentions enhancing chemosensitivity as a potential strategy, it does not present a drug intervention with a time-to-event efficacy endpoint. Therefore, it does not meet the criteria for a drug-intervention randomized trial with a primary/key secondary time-to-event efficacy endpoint. | 无 KM 图 |
| Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial.Blood | PMID 40991848PMC13319714 | 2025-Dec-18 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41124204无 PMCID | 2025-Dec-18 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41406444无 PMCID | 2025-Dec-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis.N Engl J Med | PMID 41406445PMC7618564 | 2025-Dec-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Tolvaptan pharmacokinetics and pharmacodynamics in adolescents with autosomal dominant polycystic kidney disease.Eur J Pediatr疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:非 KM 图;Fig. 3:AI 判定为 other;Fig. 4:非 KM 图。 | PMID 41407907PMC12712010 | 2025-Dec-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.Signal Transduct Target Ther疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图。 | PMID 41413016PMC12714862 | 2025-Dec-18 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial.BMC Infect Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:非 KM 图。 | PMID 41413453PMC12870096 | 2025-Dec-18 | 0.85 | The study is a Phase III randomized controlled trial with a drug (vaccine) intervention and reports original efficacy results. However, the primary efficacy endpoint (vaccine efficacy against CIN2+) is a proportion/risk reduction endpoint, not a time-to-event endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the specific cohort requirement for a time-to-event efficacy endpoint. | 无 KM 图 |
| Long-term protection from naturally acquired immunity against hepatitis E virus reinfection.Nat Commun疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:非 KM 图;Fig. 3:非 KM 图。 | PMID 41407683PMC12711902 | 2025-Dec-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Associations and predictive value of weight-adjusted waist index for cardiovascular outcomes in type 2 diabetes: evidence from the ACCORD study.Nutr J | PMID 41408264PMC12709832 | 2025-Dec-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Interrater reliability in the assessment of oral mucositis among patients receiving high-dose chemotherapy: a multicenter comparison between specialized dentists and registered nurses.BMC CancerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41408611PMC12715953 | 2025-Dec-17 | 0.85 | The record describes a Phase III randomized trial with a drug intervention (high-dose chemotherapy) and is an original result report. However, it is not eligible because the primary endpoint is the interrater reliability of oral mucositis assessment, which is a methodological/quality-of-life/safety-adjacent analysis, not a time-to-event efficacy endpoint as required (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). | 无 KM 图 |
| Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Exploratory Insights From the ODYSSEY-HCM Trial.J Am Coll CardiolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40864019无 PMCID | 2025-Dec-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR.J Am Coll CardiolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40892609无 PMCID | 2025-Dec-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial.JAMAPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41144242PMC12560030 | 2025-Dec-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.CirculationPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41321238无 PMCID | 2025-Dec-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tegileridine for moderate-to-severe acute pain following abdominal surgery: A randomized, double-blind, phase 3 clinical trial.Cell Rep Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 1:CONSORT/入组流程图;Figure 2:非 KM 图。 | PMID 41365300PMC12765830 | 2025-Dec-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma-An Exploratory Analysis of the STIC CTC Trial.Clin Cancer Res疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41020765无 PMCID | 2025-Dec-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial.Clin Cancer Res | PMID 41065506PMC12702137 | 2025-Dec-15 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| [Phase Ⅲ, multicenter, randomized, double-blinded, positive-controlled trial on the efficacy and safety of maribavir compared with valganciclovir in the treatment of post-transplant cytomegalovirus infection: Subgroup analysis of AURORA Trial in the Chinese population].Zhonghua Xue Ye Xue Za Zhi | PMID 41486656PMC12791048 | 2025-Dec-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Efficacy and safety of L-oxiracetam on cognitive function in patients with traumatic brain injury: a multicentre, randomised, double-blind, phase 3 clinical trial.Signal Transduct Target Ther已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 other;Fig. 3:森林图/亚组分析图。 | PMID 41381424PMC12698704 | 2025-Dec-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| The patient reported intraocular lens questionnaire (PR-ILQ): content validity, psychometric performance, and use in a regulated clinical trial to evaluate safety and effectiveness outcomes.J Patient Rep Outcomes已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 flow diagram。 | PMID 41385130PMC12701150 | 2025-Dec-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of daridorexant in Chinese patients with insomnia disorder: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial.SleepPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40557879无 PMCID | 2025-Dec-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41124210无 PMCID | 2025-Dec-11 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.J Clin Oncol | PMID 40991874PMC12680271 | 2025-Dec-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41187298无 PMCID | 2025-Dec-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41213101无 PMCID | 2025-Dec-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.Blood Adv | PMID 40829107PMC12686796 | 2025-Dec-09 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Twice-Daily Clopidogrel vs Ticagrelor to Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention: The TADCLOT Trial.J Am Coll CardiolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40892606无 PMCID | 2025-Dec-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Impact of tranexamic acid on postpartum hemorrhage in type 1 von Willebrand disease treated with recombinant VWF.Blood Adv入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40902088PMC12686688 | 2025-Dec-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41138601无 PMCID | 2025-Dec-09 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41175805无 PMCID | 2025-Dec-09 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial.Eur J Cancer入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | PMID 41207182无 PMCID | 2025-Dec-09 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study).Eur J CancerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41240533无 PMCID | 2025-Dec-09 | 0.85 | The study is a randomized, placebo-controlled, Phase III trial with a drug intervention (letrozole) and an HR reported. However, the primary endpoint is the 5-year incidence of invasive breast cancer (a prevention outcome), not a time-to-event efficacy endpoint in the context of treating established malignancy (e.g., OS, PFS, DFS). The criteria require a primary/key secondary time-to-event efficacy endpoint for a drug intervention trial, which is not met here. | 无 KM 图 |
| Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial.Cancer Cell疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41072417无 PMCID | 2025-Dec-08 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Hydroxychloroquine does not affect endotheliopathy or coagulopathy biomarkers in COVID-19: longitudinal results from the DisCoVeRy randomized trial.Angiogenesis已检查 1 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other。 | PMID 41353681PMC12682712 | 2025-Dec-07 | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 无 KM 图 |
| Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trial.Nat Commun已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:ROC 图;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other。 | PMID 41354738PMC12796199 | 2025-Dec-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy.J Hematol Oncol | PMID 41354932PMC12696894 | 2025-Dec-07 | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 已完成 |
| Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate vaccine in healthy infants.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41187484无 PMCID | 2025-Dec-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tolerability, safety, and preliminary immunogenicity assessment of different dosages of Quadrivalent inactivated influenza vaccine in healthy subjects aged 6-35 months: A single-center, dose-escalation, open-label phase I clinical trial.Vaccine入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41207071无 PMCID | 2025-Dec-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Serum protein profiles differ with adalimumab and ustekinumab treatment in moderately to severely active Crohn's disease.J Crohns ColitisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41258994无 PMCID | 2025-Dec-05 | 0.95 | The study is a Phase III randomized trial of drugs for Crohn's disease, not oncology. Although it meets criteria for human, randomized, phase3, and drug intervention, it fails the primary oncology requirement and lacks time-to-event efficacy endpoints, making it ineligible. | 无 KM 图 |
| Expanding insights from the VISTA phase III trial: longitudinal comparative assessment of ellipsoid zone integrity and volumetric fluid dynamics.Sci Rep已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other。 | PMID 41350590PMC12680624 | 2025-Dec-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.Blood疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40939190无 PMCID | 2025-Dec-04 | 0.80 | The record is an original results report from a Phase III oncology trial with drug interventions and time-to-event endpoints. However, it is a secondary analysis comparing outcomes of different regimens chosen by local practice, not the primary report. Critically, the record does not explicitly establish that patients were randomly assigned to the different regimens being compared (R-CHOP21 vs others). Therefore, the 'randomized' criterion for this specific analysis cannot be confirmed, making it ineligible for the cohort requiring clear randomization evidence. | 无 KM 图 |
| Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41337715无 PMCID | 2025-Dec-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma.Blood Cancer J | PMID 41345095PMC12808303 | 2025-Dec-04 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphoma.Jpn J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40891733无 PMCID | 2025-Dec-03 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.Nat Commun | PMID 41339316PMC12775477 | 2025-Dec-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |